Biomerica Secures First European Order for H. pylori Test from Major Lab Chain
Event summary
- Biomerica received its first commercial order for Hp Detect™ from a large European clinical laboratory chain, targeting the UK market.
- The order follows Hp Detect™'s MHRA registration in February 2026.
- Biomerica anticipates recurring orders as the test integrates into the customer’s routine workflow.
- H. pylori affects 45% of the population in Europe’s five largest countries, with WHO classifying it as a Class 1 carcinogen.
The big picture
This order marks a strategic validation of Hp Detect™ in the professional laboratory market, positioning Biomerica to capitalize on the growing demand for accurate H. pylori diagnostics. The WHO’s classification of H. pylori as a global health threat underscores the urgency for effective diagnostic tools, while the NHS’s guidelines ensure recurring clinical demand in the UK. Biomerica’s ability to secure this high-profile account could accelerate its broader EU and US market penetration.
What we're watching
- Market Expansion
- How Biomerica leverages this reference account to secure additional distribution partnerships across the EU and US.
- Regulatory Compliance
- Whether Biomerica can navigate regulatory approvals to expand Hp Detect™'s commercialization in other countries.
- Execution Risk
- The pace at which Biomerica can convert this initial order into sustained, high-volume demand.
Related topics